Theriva Biologics, Inc. (TOVX)
NYSEAMERICAN: TOVX · Real-Time Price · USD
1.260
0.00 (0.00%)
At close: Nov 20, 2024, 4:00 PM
1.400
+0.140 (11.10%)
After-hours: Nov 20, 2024, 7:57 PM EST
Theriva Biologics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Selling, General & Admin | 8.38 | 7.78 | 7.57 | 6.47 | 5.03 | 4.58 | |
| Research & Development | 15.64 | 14.31 | 11.72 | 7.8 | 5.13 | 11.08 | |
| Operating Expenses | 24.02 | 22.09 | 19.29 | 14.27 | 10.16 | 15.66 | |
| Operating Income | -24.02 | -22.09 | -19.29 | -14.27 | -10.16 | -15.66 | |
| Interest & Investment Income | 0.87 | 1.44 | 0.51 | 0.01 | 0.04 | 0.28 | |
| Currency Exchange Gain (Loss) | -0 | 0 | -0.04 | - | - | - | |
| EBT Excluding Unusual Items | -23.15 | -20.65 | -18.82 | -14.27 | -10.12 | -15.38 | |
| Merger & Restructuring Charges | - | - | -0.2 | - | - | - | |
| Other Unusual Items | 0.66 | 0.66 | -2.09 | - | - | - | |
| Pretax Income | -27.12 | -19.99 | -21.11 | -14.27 | -10.12 | -15.38 | |
| Income Tax Expense | -0.42 | -1.64 | -1.43 | - | - | - | |
| Earnings From Continuing Operations | -26.69 | -18.35 | -19.69 | -14.27 | -10.12 | -15.38 | |
| Minority Interest in Earnings | - | - | - | 0 | 0.07 | 0.08 | |
| Net Income | -26.69 | -18.35 | -19.69 | -14.27 | -10.04 | -15.3 | |
| Preferred Dividends & Other Adjustments | - | - | 0.34 | 8.92 | 2.51 | 0.77 | |
| Net Income to Common | -26.69 | -18.35 | -20.03 | -23.19 | -12.56 | -16.08 | |
| Shares Outstanding (Basic) | 1 | 1 | 1 | 0 | 0 | 0 | |
| Shares Outstanding (Diluted) | 1 | 1 | 1 | 0 | 0 | 0 | |
| Shares Change (YoY) | 30.03% | 5.09% | 25.76% | 541.07% | 15.65% | 163.75% | |
| EPS (Basic) | -32.52 | -28.48 | -32.66 | -47.57 | -165.13 | -244.49 | |
| EPS (Diluted) | -32.52 | -28.48 | -32.66 | -47.57 | -165.13 | -244.49 | |
| Free Cash Flow | - | -19.2 | -19.2 | -12.9 | -12.18 | -13.87 | |
| Free Cash Flow Per Share | - | -29.80 | -31.31 | -26.47 | -160.13 | -210.99 | |
| EBITDA | -23.87 | -21.96 | -19.21 | -14.19 | -9.96 | -15.42 | |
| D&A For EBITDA | 0.15 | 0.14 | 0.09 | 0.09 | 0.2 | 0.24 | |
| EBIT | -24.02 | -22.09 | -19.29 | -14.27 | -10.16 | -15.66 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.